^
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Sensitive
:
C3
Lung Cancer - 3wk
MGAM mutation
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Sensitive
:
C3
Front Pharmacol - 3wk
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
Mvasi (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin + pemetrexed
Sensitive
:
A1
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + erlotinib
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
sintilimab
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive
:
A1
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive
:
A1
ALK mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pemetrexed
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
VC
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
EP
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
CaT
Sensitive
:
A2
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
gefitinib
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive
:
A2
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
GemVin
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
GT
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
GC
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
carboplatin + pemetrexed
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
GemCarbo
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our